Compounds > kt2 962
Page last updated: 2024-11-13

kt2 962

Description

6-isopropyl-3-(4-(4-chlorobenzenesulfonylamino)butyl)azulene-1-sulfonic acid sodium salt: structure given in first source; a prostaglandin endoperoxide receptor antagonist; RN given refers to the mono-sodium salt; RN for parent cpd not available 4/93 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23661969
CHEMBL ID262655
SCHEMBL ID2920348
MeSH IDM0214979

Synonyms (19)

Synonym
kt 2-962
6-isopropyl-3-(4-(4-chlorobenzenesulfonylamino)butyl)azulene-1-sulfonic acid sodium salt
1-azulenesulfonic acid, 3-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-6-(1-methylethyl)-, monosodium salt
3-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-6-(1-methylethyl)-1-azulenesulfonic acid monosodium salt
unii-w9f1s1h9lp
kt2-962
129648-96-0
w9f1s1h9lp ,
kt2 962
CHEMBL262655 ,
SCHEMBL2920348
DTXSID40156212
J343.474E ,
kt2962
Q27292501
sodium;3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-propan-2-ylazulene-1-sulfonate
kt-2962
6-isopropyl-3-(4-(4-chlorophenylsulfonylamino)butyl)azulene-1-sulfonic acid sodium salt
6-isopropyl-3-(4-(p- chlorobenzenesulfonylamino)-butyl)-azulene-1-sulfonic acid sodium salt
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID165498Compound was tested for agonist activity on rabbit aorta1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID165375Tested for the concentration that causes 50% relaxation when contraction in rabbit aorta was induced by 3 x 10 E -8 M of U-46619.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID232743Selectivity index for the TXA2 t-receptor was the difference between the IC50 values in the aggregation and contraction assay1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID165497Compound was tested for agonist activity on rabbit PRP1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID167793Compound was tested for the inhibition U-46619 (3 x10 E -8 M) induced vascular contraction (TXA2 tao receptor) in rabbit thoracic aorta1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID167807Displacement of specific binding of [3H]SQ-29,548 to rabbit gel-filtered platelets1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID167790Compound was tested for the inhibition U-46619 (3 x10 E -8 M) induced platelet aggregation (TXA2 alpha receptor) in rabbit platelet rich plasma1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID232748Selectivity index is the difference between the IC50 values in the aggregation and contraction assays1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID92220Effect on TXB2 formation of human platelets1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID165374Tested for the concentration that cause 50% inhibition of the maximum aggregation with rabbit platelet-rich plasma induced by 2.5 x 10 E -6 M of U-466191990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID179228Inhibition of U-46619 (3x10E-8 M) induced contraction in rat thoracic aorta1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (75.00)18.2507
2000's2 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histamine
[no description available]		1.9810aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		1.9810aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
pyrilamine
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.		1.9810aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
azulene
[no description available]		1.9910azulenes;
mancude carbobicyclic parent;
ortho-fused bicyclic arene		plant metabolite;
volatile oil component
sulotroban
sulotroban: thromboxane receptor antagonist		2.3820
bm 13505
daltroban: thromboxane antagonist		2.0110
nafagrel
nafagrel: structure given in first source		210
thromboxane a2
Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.		2.6830epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)		2.420
ConditionIndicatedRelationship StrengthStudiesTrials
Injury, Myocardial Reperfusion
[description not available]		02.0110
Death, Sudden
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.		02.3920
Thrombopenia
[description not available]		01.9810
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		01.9810
Pulmonary Hypertension
[description not available]		02.3920
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.3920
Glomerulonephritis, Lupus
[description not available]		0210
Nephritis
Inflammation of any part of the KIDNEY.		0210
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).		0210
chemdatabank.com